- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06056817
Chronic Evaluation of Novel Pacemaker System
September 21, 2023 updated by: Calyan Technologies
The primary study objective is to evaluate the feasibility, initial clinical safety and potential effectiveness of the Calyan Pacemaker system.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an early feasibility study, designed to evaluate the initial clinical safety, device functionality and stability and potential effectiveness of the Calyan pacemaker.
The Calyan device will be implanted, and if acute success criteria are met, chronic pacing will be delivered over a 3-month primary follow-up period, with subsequent extended follow-up of all patients.
The data from this study will be used to justify the design of a larger prospective pivotal study that will assess the safety and effectiveness of the Calyan pacemaker device.
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Imad Libbus, PhD
- Phone Number: 763-657-1480
- Email: imad@calyantech.com
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 or above
- Willing and capable of providing informed consent
- Class I or IIa indication for implantation of a single-chamber ventricular pacemaker, according to ACC/AHA/HRS guidelines
- A life expectancy of at least one year, and is a suitable candidate based on overall health and well-being
Exclusion Criteria:
- Patients with complete AV block or other pacemaker-dependent conditions
Patients in whom a substernal device implant should be avoided:
- Any prior sternotomy;
- Any prior medical condition or procedure that leads to adhesions in the anterior mediastinal space;
- Any marked sternal abnormality, such as pectus excavatum or pectus carinatum
- Prior abdominal surgery in the epigastric region
- Planned sternotomy
- Prior or planned chest radiotherapy
- Hiatal hernia that distorts mediastinal anatomy
- Adhesions in the anterior mediastinal space
- Severe obesity so that subxiphoid/substernal tunneling cannot be safely performed
- Patients with severe RV dilation, gross hepatosplenomegaly, or severe obesity such that subxiphoidal/substernal tunneling cannot be safely performed
- Patients with a class III indication for a permanent pacemaker
- Patients with decompensated heart failure not due to bradycardia and expected to worsen with chronic RV pacing
- Patients with an implanted cardiac pacemaker, cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device, or planned implantation of a cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device
- Patients with a current or planned implantation of a substernal device, or any implanted device that would interfere with the implantation or operation of a substernal device
- Patients who have previously undergone an open-heart surgical procedure.
- Patients with an active infection
- Patient on chronic oral anticoagulation which cannot be temporarily discontinued for surgery
- Patients with a condition in which pericardial pacing would be difficult or impossible, such as acute pericarditis, chronic pericardial effusion or pericardial thickening or calcification, cardiac tamponade, or chronic restrictive pericarditis
- Patients who have tested positive for the COVID-19 in the past 3 months, or are currently showing symptoms consistent with COVID-19
- Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding
- Subjects with a life expectancy of less than 12 months
- Patients who are currently enrolled or planning to participate in any concurrent clinical study with an investigational therapy
- Patients with decompensated heart failure expected to worsen with chronic RV pacing
- Patients with COPD with oxygen dependence
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Chronic implantation of the Calyan pacemaker device
|
The Calyan pacemaker is a device designed for implantation in the chest below the xiphoid process, and includes a FlexArm containing stimulation and sensing electrodes.
The Calyan pacemaker is implanted using a set of delivery tools and clipped onto the xiphoid process; the FlexArm electrodes are oriented to make contact with the pericardial surface of the heart.
Pacing parameters are adjusted wirelessly with a tablet-based programmer that communicates with the Calyan pacemaker via secure Bluetooth.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of procedure and device related serious adverse events (SAEs)
Time Frame: 3 months
|
Rate of procedure and device related serious adverse events (SAEs) at 3 months post-implant.
|
3 months
|
Number of patients with successful chronic ventricular pacing
Time Frame: 3 months
|
Proportion of patients with successful chronic ventricular pacing, including successful pacemaker implantation and chronic capture of the ventricle, during the 3-month primary follow-up period.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Imad Libbus, PhD, Calyan Technologies
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2023
Primary Completion (Estimated)
July 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
September 21, 2023
First Submitted That Met QC Criteria
September 21, 2023
First Posted (Actual)
September 28, 2023
Study Record Updates
Last Update Posted (Actual)
September 28, 2023
Last Update Submitted That Met QC Criteria
September 21, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT-05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bradycardia
-
Augusta UniversityCompletedFetal BradycardiaUnited States
-
University of Maryland, BaltimoreCompleted
-
University of Sao Paulo General HospitalCompletedFetal Bradycardia | Hypertonic Uterine | CatecholaminesBrazil
-
Chun Chieh WangEnrolling by invitation
-
University of ExeterRoyal Devon and Exeter NHS Foundation TrustCompletedSVT | Vagal BradycardiaUnited Kingdom
-
Abbott Medical DevicesCompletedStandard Bradycardia Pacing IndicationFrance, Germany, Italy, Japan
-
Medical University of GdanskCompletedBradycardia During Pulling of EyeballPoland
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
South Western Ambulance Service NHS Foundation...Royal Devon and Exeter NHS Foundation Trust; Academic Health Science CentresCompletedEmergencies | SVT | Vagal BradycardiaUnited Kingdom
-
Unyime ItukRecruitingFetal Heart Rate or Rhythm Abnormality Affecting Fetus | Fetal Bradycardia Complicating Labor and Delivery | Fetal Bradycardia During LaborUnited States
Clinical Trials on Calyan Pacemaker
-
Ajou University School of MedicineRecruitingObesity | Arrhythmias, Cardiac | Cardiovascular Morbidity | Pacemaker ComplicationKorea, Republic of
-
Region GävleborgUnknown
-
Abbott Medical DevicesTerminated
-
Imperial College LondonBritish Heart FoundationRecruitingBradycardia | Left Bundle Branch Area Pacing | His Bundle Pacing | Right Ventricular Pacing | PacingUnited Kingdom
-
Massachusetts General HospitalMedtronicRecruiting
-
Manchester University NHS Foundation TrustAbbott Medical Devices; British Heart FoundationCompletedVentricular Dysfunction | Ventricular RemodellingUnited Kingdom
-
University of CalgaryCalgary Health TrustTerminatedAtrial Fibrillation | Cardiac Pacing, ArtificialCanada
-
Arun RaoMedtronicCompletedSinus Node DysfunctionUnited States
-
Insel Gruppe AG, University Hospital BernUniversity of BernRecruitingHeart Diseases | Cardiovascular Diseases | Arrhythmias, Cardiac | Cardiac PacemakerSwitzerland
-
Medtronic Cardiac Rhythm and Heart FailureSuspendedHeart Failure With Preserved Ejection Fraction | Concentric HypertrophyUnited States